NAWS Set for September in Boston
The Nucleic Acid World Summit is to be held on Sept. 15 -17 at the Radisson Hotel in Boston.
The event will feature more than 65 speakers from 60 different companies. Topics to be covered include siRNAs, antisense, ribozymes, alternative splicing/RNA trans-splicing, intellectual property, and investment trends.
Details about the conference can be found at http://www.srinstitute.com/part_iter_site_page.cfm?iteration_id=550.
NYAS’ First RNAi Symposium Date, Keynote Speaker Roster Finalized
The New York Academy of Sciences has scheduled its first half-day RNAi symposium for Oct. 27, at Rockefeller University’s Caspary Hall.
The meeting will begin at 2 pm and includes keynote presentations by MIT’s Phillip Sharp on the biology and possible uses of siRNAs and by Cenix Biosciences’s Chris Echeverri on the “art of genome-wide RNAi.”
The symposium will also feature talks by four New York-area researchers, who will be determined by abstract submission.
EuroForum RNAi Conference scheduled for Mid-November
EuroForum International is holding an RNAi conference on November 17 and 18 that will bring together representatives of both the drug industry and academic institutions to discuss the technology, its current uses, and barriers to its future development.
The conference will be held in central London at a venue yet to be confirmed. Speakers will include Chris Echeverri, of Cenix BioScience; Michal Janitz, of the Max Planck Institute for Molecular Genetics; and Andrew Clifton, from AstraZeneca.
Details about the event, including registration and pricing, can be found at http://www.ef-international.co.uk/index.cfm?conference=2333.
Intradigm Develops siRNA Inhibitor of SARS
Intradigm announced that it had developed siRNA capable of achieving 90 percent inhibition of the SARS virus in cell-based studies.
The company collaborated with Qiagen to design the siRNA, which targeted specific genes throughout the SARS genome. Qiagen synthesized the siRNA, and the product was tested in laboratories in Hong Kong and Guangzhou, China, using non-human primate cells exposed to the SARS virus.
The effort was sponsored by Hong Kong’s Top Biotech and the provincial government of Guangdong.